Blockchain Registration Transaction Record

TransCode's TTX-MC138 Shows 71% Disease Control in Phase 1a

TransCode Therapeutics reports updated Phase 1a data for TTX-MC138, showing 71% disease control and no dose-limiting toxicities in advanced solid tumors.

The updated data from TransCode Therapeutics' Phase 1a trial of TTX-MC138 offer a glimmer of hope for patients with advanced solid tumors who have exhausted other treatment options. The high rate of stable disease and the absence of dose-limiting toxicities suggest that TTX-MC138 is well-tolerated and may provide clinical benefit by slowing disease progression. The GMI analysis, which showed a progression-free interval at least 30% longer than prior therapy in 40% of evaluable patients, is particularly encouraging as it indicates a potential meaningful clinical advantage over existing treatments. If these results are confirmed in larger trials, TTX-MC138 could become a valuable addition to the treatment landscape for metastatic cancers, addressing a significant unmet need. For investors, these data de-risk the program and support further development, potentially leading to partnerships or accelerated approval pathways. The immune effects observed also validate the company's RNA therapeutics approach, which could extend to other candidates in its pipeline. Overall, this news matters because it represents a step forward in the fight against hard-to-treat cancers and highlights the potential of RNA-based therapies to make a difference.